REPORTABLE CASES – MISSISSIPPI

For cases diagnosed 10/2006 or later

The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable neoplasms diagnosed on or after January 1, 1996 should be reported to the Mississippi Cancer Registry.

REPORTABLE NEOPLASMS

- Malignant neoplasms (exclusions noted below)
- Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)
- Carcinoma in-situ (exclusions noted below)
- Carcinoid, NOS (excluding appendix, unless stated to be malignant)
- Pilocytic/juvenile astrocytoma is listed as 9421/1 in ICD-O-3, is reportable, and should be coded to 9421/3.
- Squamous intraepithelial neoplasia grade III of vulva [VIN], vagina [VAIN], and anus [AIN] beginning with 2001 cases.

Note:

- Primary Tumors that originate in a mucous membrane are reportable and include the following: Lip, Anus, Labia, Clitoris, Vulva, Vagina, Prepuce, Penis, Scrotum
- ➤ Melanoma is reportable

NON-REPORTABLE NEOPLASMS

- Basal and squamous cell carcinomas of the skin (8090-8110)
- Epithelial carcinomas of the skin (8010-8045)
- Papillary and squamous cell carcinomas of the skin (8050-8084)
- Malignant neoplasms, NOS of the skin (8000-8004)
- Carcinoma in-situ of the cervix (8012)
- Intraepithelial neoplasms of the cervix (8077/2) or prostate (8148/2)
- Borderline cystadenomas (8442, 8451, 8462, 8472, 8473), of the ovaries with behavior code "1" are **not** collected as of January 1, 2001
- Cyst, brain or CNS tumor that does not have an ICD-O-3 code as of January 1, 2004

COMPREHENSIVE SCREENABLE LIST

The following lists should aid the reporter in determining which admissions (inpatient and outpatient) should be **reviewed for reportablility**.

| ICD-9-CM Codes | Diagnosis | |
|-------------------------|--|--|
| Code Ranges | Preferred ICD-O-3 Terminology | |
| 140.0 through 208.9 | Malignant neoplasms | |
| 225.0 through 225.9 | Benign & Borderline Neoplasms of Central Nervous System | |
| 230.0 through 234.9 | Carcinoma In Situ | |
| 235.0 through 238.9 | Neoplasms of Uncertain Behavior | |
| 239.0 through 239.9 | Neoplasms of unspecified behavior | |
| Individual Codes | Preferred ICD-O-3 Terminology | |
| 042 | AIDS (review records for AIDS-related malignancies) | |
| 203.1 | Plasma cell leukemia (9733/3) | |
| 205.1 | Chronic neutrophilic leukemia (9963/3) | |
| 227.3 | Pituitary (body, fossa, gland, lobe) | |
| 227.3 | Craniopharyngeal (duct, pouch) | |
| 227.4 | Pineal (body, gland) | |
| 230.6 | Squamous Intraepithelial Neoplasia Grade III of the Anus [AIN] | |
| 233.3 | Squamous Intraepithelial Neoplasia Grade III of the Vagina | |
| | [VAIN] and Vulva [VIN] | |
| 238.4 | Polycythemia vera (9950/3) | |
| 238.5 | Malignant mastocytoma (9740/3) | |
| 238.6 | Solitary plasmacytoma (9731/3) | |
| 238.6 | Extramedullary plasmacytoma (9734/3) | |
| 238.71 | Essential thrombocythemia (9962/3) | |
| 238.72 | Refractory cytopenia with multilineage dysplasia (9985/3) | |
| 238.72 | Therapy-related myelodysplastic syndrome (9987/3) | |
| 238.72 | Refractory anemia (9980/3) | |
| 238.72 | Refractory anemia with ringed sideroblasts (9982/3) | |
| 238.73 | Refractory anemia with excess blasts(9983/3) | |
| 238.73 | Refractory anemia with excess blasts in transformation [obs]* | |
| | (9984/3) | |
| 238.74 | Myelodysplastic syndrome with 5q-syndrome (9986/3) | |
| 238.76 | Myelosclerosis with myeloid metaplasia (9961/3) | |
| 238.79 | Acute myelofibrosis (9931/3) | |
| 238.79 | Chronic myeloproliferative disease (9960/3) | |
| 273.2 | Gamma heavy chain disease; Franklin's disease | |
| 273.3 | Waldenstrom's macroglobulinemia | |
| 273.9 | Unspecified disorder of plasma protein metabolism (screen for | |
| | potential 273.3 miscode) | |
| 288.3 | Hypereosinophilic syndrome (9964/3) | |
| 289.83 | Myelofibrosis with agnogenic myeloid metaplasia (9961/3) | |

^{*} Note: This is an obsolete diagnostic term. The condition should be correctly coded to 205.0, acute myelogenous leukemia

Admissions with the following procedure codes **must** be screened for reportable neoplasms.

| ICD-9-CM Codes | Procedure Description |
|----------------|--|
| V07.3 | Other prophylactic chemotherapy |
| V07.8 | Other specified prophylactic measures |
| V58.0 | Admission for radiotherapy |
| V58.1 | Admission for chemotherapy |
| V66.1 | Convalescence following radiotherapy |
| V66.2 | Convalescence following chemotherapy |
| V67.1 | Follow-up exam following radiotherapy |
| V67.2 | Follow-up exam following chemotherapy |
| V71.1 | Observation for suspected malignant neoplasm |
| V76.0-V76.9 | Special screening for malignant neoplasms |

The following are **exclusions** and **do not** need to be to be reported to the MCR.

| Morphology Codes | Diagnosis/ Terminology |
|------------------|---|
| 8000-8004 | Neoplasms, malignant, NOS of the skin |
| 8010/2 | Carcinoma in-situ of cervix |
| 8010-8045 | Epithelial carcinomas of the skin |
| 8050-8084 | Papillary and squamous cell carcinomas of |
| | the skin |
| 8077/2 | Squamous Intraepithelial Neoplasia, grade |
| | III of cervix |
| 8090-8110 | Basal cell carcinomas of the skin |
| 8148/2 | Prostatic Intraepithelial Neoplasia |

AMBIGUOUS TERMINOLOGY

| Terms That Constitute a Diagnosis | Terms That <i>Do Not</i> Constitute a |
|-----------------------------------|---------------------------------------|
| | Diagnosis |
| Apparent(ly) | Cannot be ruled out |
| Appears to | Equivocal |
| Comparable with | Possible |
| Compatible with | Potentially malignant |
| Consistent with | Questionable |
| Favor(s) | Rule out |
| Malignant appearing | Suggests |
| Most likely | Worrisome |
| Presumed | |
| Probable | |
| Suspect | |
| Suspicious | |
| Typical of | |

Exceptions:

- If a cytology is reported as suspicious, do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.
- Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

There are other ambiguous terms used by physicians that are related to staging. Some may indicate tumor involvement or extension, while others are not considered to be involvement. Refer to *Collaborative Staging Manual and Coding Instructions*, page I-20, for a listing of those terms.